Day: March 13, 2025

Achieves alignment with U.S. Food and Drug Administration (FDA) on regulatory path for potential accelerated approval of iopofosine I 131 as a treatment for Waldenström macroglobulinemia (WM) Evaluating timing for Phase 1 solid tumor studies; Auger-emitting radioconjugate prepared for Phase 1b; plans to submit an IND for alpha-emitting radioconjugate; Company to host webcast and conference call at 8:30 AM ET today FLORHAM PARK, N.J., March 13, 2025 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2024, and provided a corporate update. “In 2024 the company showcased the efficacy and safety of iopofosine I...

Fourth Quarter Revenue was $519.9 million, an 8.6% increase over the prior year periodGross margin increased 15.7% to $171.7 million compared to Q4 2023Fourth Quarter Net income was $29.2 million compared to net loss of $25.7 million for the comparable prior year periodAdjusted Net income was $11.1 million, an increase of $14.3 million compared to Q4 2023Adjusted EBITDA for Q4 2024 was $55.2 million, a 42.8% increase as compared to Q4 2023 Full Year 2025 Revenue guidance between $2.10 – $2.12 billionFull Year 2025 Adjusted EBITDA guidance between $190 – $194 millionATLANTA, March 13, 2025 (GLOBE NEWSWIRE) — Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced financial...

WILLIAMSBURG, Va., March 13, 2025 (GLOBE NEWSWIRE) — Sotherly Hotels Inc. (NASDAQ: SOHO), (“Sotherly” or the “Company”), a self-managed and self-administered lodging real estate investment trust (a “REIT”), today reported its consolidated results for the fourth quarter and year ended December 31, 2024. The Company’s results include the following*:  Three Months Ended     Years Ended    December 31, 2024     December 31, 2023     December 31, 2024     December 31, 2023    ($ in thousands except per share data)     ($ in thousands except per share data)  Total revenues $ 43,952     $ 42,148     $ 181,894     $ 173,838  Net (loss) income   (1,118 )     (770 )     1,180       3,810  Net loss attributable to common stockholders   (3,034 )     (2,683 )     (6,675 )     (4,036 )                       EBITDA   9,383       8,490       40,883       39,079  Hotel...

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate UpdateLandmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potential milestones of up to about $2.1 billion plus royalties on sales upon commercialization ACI-24.060 ABATE Phase 1b/2 trial showed encouraging interim safety and tolerability data in Down syndrome (DS) cohort; further interim results in Alzheimer’s disease (AD) and DS expected in 2025 Enrollment progress in JNJ-2056 (ACI-35.030) ReTain Phase 2b trial in preclinical AD patients triggered second milestone payment of CHF 24.6 million; JNJ-2056 granted U.S. FDA Fast Track Designation in AD ACI-7104.056 VacSYn Phase 2 trial demonstrated positive interim safety and immunogenicity results in Parkinson’s disease (PD); further interim results in H1...

HOUSTON, March 13, 2025 (GLOBE NEWSWIRE) — U.S. Energy Corporation (NASDAQ: USEG, “U.S. Energy” or the “Company”), a growth-focused energy company engaged in operating a portfolio of high-quality producing assets, today reported financial and operating results for the fourth quarter and year ended December 31, 2024. FULL YEAR 2024 HIGHLIGHTSContinued the divestment of legacy non-core assets during 2024, generating $13.5 million in net sales proceeds used for development of the Company’s industrial gas project in Montana, debt repayment, and accelerated shareholder returns program. Total daily production in 2024 averaged 1,136 Boe/d; oil production averaged 702 Bbl/d. Revenue totaled $20.6 million with oil sales of $18.2 million and natural gas and liquids sales of $2.5 million. Lease operating expense of $11.2 million,...

SHENZHEN, China, March 13, 2025 (GLOBE NEWSWIRE) — Xunlei Limited (“Xunlei” or the “Company”) (Nasdaq: XNET), a leading technology company providing distributed cloud services in China, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights:Total revenues were US$84.3 million, representing an increase of 9.3% year-over-year.Subscription revenues were US$34.4 million, representing an increase of 9.0% year-over-year.Cloud computing revenues were US$22.7 million, representing a decrease of 25.6% year-over-year. Live-streaming and other internet value-added services (“Live-streaming and other IVAS”) revenues were US$27.2 million, representing an increase of 80.7% year-over-year.Gross profit was US$43.6...

CALGARY, Alberta, March 13, 2025 (GLOBE NEWSWIRE) — Calfrac Well Services Ltd. (“Calfrac” or “the Company”) (TSX: CFW) announces its financial and operating results for the three months and year ended December 31, 2024. The following press release should be read in conjunction with the management’s discussion and analysis and annual consolidated financial statements and notes thereto as at December 31, 2024. Readers should also refer to the “Forward-looking statements” legal advisory and the section regarding “Non-GAAP Measures” at the end of this press release. All financial amounts and measures are expressed in Canadian dollars unless otherwise indicated. Additional information about Calfrac is available on the SEDAR+ website at www.sedarplus.ca, including the Company’s Annual Information Form for the year ended December 31,...